Conference Details - Agenda

View all Conferences

Continuing Education Information

Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Current Trends in Genitourinary Malignancies

The Westin Pasadena
Pasadena, CA
October 31, 2009

Saturday, October 31, 2009

7:30 am Registration and Continental Breakfast
7:50 am Welcome and Introductions
Advances in Kidney Cancer
8:00 am Presession Survey
8:05 am The Role of Surgery With New Therapeutic Regimens
Monish Aron
8:30 am Treating Advanced Renal Cell Carcinoma: Integrating the Algorithm and Individualizing Therapy
Robert A. Figlin
8:55 am Case-Based Panel Discussion
9:20 am Postsession Survey
9:25 am Break
Current Management of Prostate Cancer
9:40 am Presession Survey
9:45 am Epidemiology, Screening, and Prevention of Prostate Cancer: A 2009 Update
10:10 am Management of PSA Relapse
Mitchell Gross
10:35 am Androgen Deprivation Therapy: A 2009 Perspective
Charles J. Ryan
11:00 am Immunotherapy for the Treatment of Prostate Cancer
Tanya B. Dorff
11:25 am Can We Improve Upon Standard Taxane Therapy to Treat Metastatic Prostate Cancer?
Nicholas J. Vogelzang
11:50 am Postsession Survey
11:55 am Break to Serve Lunch
12:15 pm Challenging Cases in Prostate Cancer: Interactive Panel Discussion
Current Approaches to Bladder Cancer
1:00 pm Presession Survey
1:05 pm Adjuvant and Neoadjuvant Chemotherapy for Bladder Cancer
Ronald B. Natale
1:30 pm Standard Chemotherapy and Novel Agents for Metastatic Bladder Cancer
Matthew D. Galsky
1:55 pm Interactive Case Discussion
2:20 pm Postsession Survey and Closing Comments
2:30 pm Adjourn

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology
  2. Bristol-Myers Squibb
  3. sanofi-aventis U.S.